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2 ABBREVIATIONS 
 
APC antigen presenting cell 
BBB blood brain barrier 
BCR B cell receptor 
bp base pair 
CD cluster of differentiation molecule 
cM centiMorgan 
CNS central nervous system  
CTLA-4 cytotoxic T lymphocyte associated antigen 4 
DCE denaturant capillary electrophoresis 
DNA deoxyribonucleic acid 
DZ dizygotic twins 
EDSS expanded disability status scale 
FS functional systems  
FSS functional system score 
HLA human leukocyte antigen 
ICAM intracellular adhesion molecule 
ICOS inducible co-stimulatory molecule 
Ig  immunoglobulin 
IL interleukin  
JRA juvenile rheumatoid arthritis 
k kilo  
LD linkage disequilibrium 
MHC major histocompatibility complex 
MR magnetic resonance imaging 
MS Multiple Sclerosis 
MZ monozygotic twins 
OR odds ratio 
PCR polymerase chain reaction 
PP-MS primary progressive Multiple Sclerosis 
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RFLP restriction fragment length polymorphism 
RR-MS relapsing remitting Multiple Sclerosis 
SH2D2A SH2 domain protein 2A gene 
SNP single nucleotide polymorphism 
TCR T cell receptor 
Th cell T helper cell 
TNF tumor necrosis factor 
TSAd T cell specific adaptor protein 
VNTR variable number of tandem repeats 
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4 GENERAL INTRODUCTION 
 
4.1  Multiple Sclerosis 
Multiple Sclerosis (MS) is a chronic demyelinating disease of the central nervous system 
(CNS) affecting young adults. MS is one of the most frequent causes of major 
neurological disability among people in the western world. In a Norwegian study 
including patients from the Oslo area the prevalence among patients of native Norwegian 
ancestry was found to be 136/100 0001. This is in accordance to earlier reports that the 
south-eastern part of Norway is among the regions with the highest MS prevalence in the 
country and in the world2,3. In Nord-Trøndelag County a high prevalence is also shown; 
163.6/100 000 which is among the highest ever reported in Norway4 (Figure 1).  
Vestfold: 86/105
Nord-Trøndelag 163/105
Hordaland 60/105
Møre and Romsdal 75/105
Oslo 126/105 -142/105
Troms and Finnmark 73/105
Figure 1: Prevalence of Multiple Sclerosis (MS) in Norway
 
The majority of the patients are affected by relapsing remitting MS (RR-MS), which is 
characterized by episodic attacks of neurological deficits, followed by periods of 
remission. The rate of disease progression may vary, but almost all RR-MS patients 
develop a secondary progression disease course, so-called secondary progressive (SP) 
MS5. The remaining 20 % of the MS patients develop a primary progressive disease 
course, so-called PP-MS. These do not experience acute relapses, but develop the 
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symptoms of neurological deficits progressively. Females are affected twice as ofte
males, and the mean age at onset is usually between the age of 20 and 40 years
n as 
he symptoms of MS depend on the location of the inflammatory and demyelinating 
 
LESION 
L : 
SIGNS/SYMPTOMS: 
6. 
 
T
lesions within the CNS, and are therefore very variable as shown in Table 1. 
 
OCATION
Cerebrum & Balance problems, speech problems, coordination, 
Cerebellum tremor 
Motor nerve Muscle weakness, ision  spasticity paralysis, v
tracts problems, bladder and bowel problems 
Sen rve Alte ing sory ne red sensation, numbness, prickling, burn
tract sensation 
 the disease. From http://www.msfacts.org/info/info_symptoms.html
 
 RR-MS the disease begins with an acute or subacute onset of neurological 
s may 
lready 100 years ago Charcot described the clinical and pathological characteristics of 
s6. These 
 then 
Table 1: Possible location of the Multiple Sclerosis (MS) lesions and symptoms and signs of 
In
abnormalities, a so-called MS attack, MS relapse or MS schub. Early symptom
include numbness, paresthesia, paresis, double vision, optic neuritis, and ataxia and 
bladder control problems. Also more unspecific symptoms as depression, emotional 
lability, fatigue and pain are commonly seen. 
 
A
MS5. Still the MS diagnosis is mainly based on the patient history and clinical 
examination. In 1983 Poser et al published a set of criteria for research purpose
criteria are now used also for clinical practice. The MS-diagnosis is based on the history 
of at least two attacks affecting more than one anatomical site in CNS (so-called 
dissemination in time and place). In 2001 the MS criteria were revised by “The 
International Panel on MS Diagnosis” 7. Magnetic resonance imaging (MR) was
integrated in the clinical diagnostic criteria. 
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 xpanded Disability Status Scale (EDSS) is a classification system of MS8. The EDSS 
 
SS 
y. 
 
E
quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a
Functional System Score (FSS) in each of these. The FS are as follows; pyramidal, 
cerebellar, brainstem, sensory bowel and bladder, visual, cerebral and other. The ED
score 0.0 means normal neurological examination, whereas score 10.0 is death due to 
MS. EDSS steps between 1.0 and 4.5 refer to people with MS who are fully ambulator
EDSS steps between 5.0 and 9.5 are defined by the impairment to ambulation. The EDSS
can be used by Neurologist to follow the progression of MS disability, evaluate treatment 
results and for scientific purposes. For more details see the Table 2 below.  
 
0.0 Normal neurological examination 
1.0 No disability, minimal signs in one FS 
1.5 No disability, minimal signs in more than one FS 
2.0 Minimal disability in one FS 
2.5 inimal disability in two FS Mild disability in one FS or m
3.0 Moderate disability in one FS, or mild disability in three or four FS. Fully ambulatory 
3.5 Fully ambulatory but with moderate disability in one FS and more than minimal disability in 
several others 
4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite 
 relatively severe disability; able to walk without aid or rest some 500 meters
4.5 Fully ambulatory without aid, up and about much of the day, able to work a full day, may 
otherwise have some limitation of full activity or require minimal assistance; characterized 
by relatively severe disability; able to walk without aid or rest some 300 meters. 
5.0 Ambulatory without aid or rest for about 200 meters; disability severe enough to impair full 
daily activities (work a full day without special provisions) 
5.5 Ambulatory without aid or rest for about 100 meters; disability severe enough to preclude 
full daily activities 
6.0 Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 
without resting 100 meters with or 
6.5 Constant bilateral assistance (canes, crutches, braces) required to walk about 20 meters 
without resting 
7.0 Unable to walk beyond approximately five meters even with aid, essentially restricted to 
wheelchair; wheels self in standard wheelchair and transfers alone; up and about in 
wheelchair some 12 hours a day 
7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; 
wheels self but cannot carry on in standard wheelchair a full day; May require motorized 
wheelchair 
8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed 
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itself much of the day; retains many self-care functions; generally has effective use of arms 
8.5 Essentially restricted to bed much of day; has some effective use of arms retains some self 
care functions 
9.0 Confined to bed; can still communicate and eat. 
9.5 Totally helpless bed patient; unable to communicate effectively or eat/swallow 
 Death due to MS 10.0
 
The prognosis of MS is highly variable and difficult to predict. A review from 20019 
analyzed possibilities for prediction of a benign course of MS. Especially, onset with 
optic neuritis, onset before the age of 40 years, absence of pyramidal signs at 
presentation, duration of first remission more than one year, and only one exacerb
the first 5 years after onset of MS, were associated with a benign course, which was seen 
in 26.7% of the cases. 
ation in 
anded Disability Status Scale (EDSS) for Multiple 
Sclerosis (MS) patients.  
From http://www.mult-sclerosis.org/expandeddisabilitystatusscale.html 
Table 2: Kurtzke Exp
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4.2 The immune system 
The function of the immune system is to recognize and eliminate invading foreign 
organisms. The immune system must therefore distinguish self from non-self and 
dangerous from non-dangerous. Immune responses are classified in several ways: as 
primary (induced by first contact with antigen) or secondary (renewed contact with 
antigen); as humoral immunity mediated by immunoglobulins (Igs) produced by B-
lymphocytes (B-cells) or as cellular immunity mediated by cytotoxic T-lymphocytes (T-
cells). ”Adaptive immunity” gives a specific lifelong immunity. “Innate immunity” is not 
specific and consist of mainly macrophages and neutrophiles which are the first line of 
defense against foreign microorganism 10,11. 
4.2.1 Components of the immune system 
Antigens are substances with a molecular surface structure that trigger an immune 
response; i.e. production of antibodies or involvement in the specific antigen-antibody 
reaction. Antigens are often classified according to source, as exogenous or endogenous.  
Major histocompatibility complex (MHC) molecules are surface molecules encoded 
by the class I or class II regions of the MHC gene, in humans known as the human 
leukocyte antigen (HLA) molecule and gene. Class I molecules are found on all cells and 
are specialized to present antigen-peptide synthesized within the host cells. The molecule 
can therefore present viral and tumor antigens. MHC class II molecules are found mainly 
on antigen presenting cells (APCs). They are specialized to present antigen-peptide 
derived from outside the host cells, such as bacterial fragments and other extracellular 
antigens. 
B-cells are lymphocytes that express the B-cell receptor (BCR). The BCR is a membrane-
bounded immunoglobulin (IgM) an antibody, and serve as the cell’s receptor for antigen. 
On activation by an antigen and with stimulatory signals and growth factors released 
locally by T helper (Th) cells, the B-cell differentiates into a so-called plasma cell. The 
plasma cells produce antibody molecules of the same antigen specificity as the receptor 
on the B-cells. The secreted antibodies have the capacity to bind to the inducing antigens 
and label them for further phagocytosis by macrophages. 
T-cells are lymphocytes that usually express the cluster of differentiation 3 (CD3) 
molecules. Almost every T-cell expresses T-cell receptors (TCRs). The TCR is an 
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antibody-like molecule located on the surface membrane on the T-cell. When the antigen-
peptide is presented in the cleft of either MHC class I or class II molecules, the T-cells 
can recognize the antigen, and this stimulates to further signal in the T-cells. All activated 
T-cells secrete interleukin-2 (IL-2), which stimulate to production of IL-2 receptors and 
proliferation of T-cells.  
The T-cells fall into two classes that perform different but overlapping functions. The two 
classes are distinguished by the expression of the surface markers CD4 and CD8. These 
adhesion molecules on the T-cell surface act as co-receptors in the interaction between 
the TCR and the antigen-peptide-MHC-complex on the APC. CD4 is expressed on 
approximately 60 % of mature T-cells, whereas CD8 is expressed on about 30% of the T-
cells. The CD4/CD8 ratio in normal healthy individuals is therefore about 2:1. 
The CD4+ T-cells are “helper” T-cells (Th-cells). Their main function is as regulatory 
cells which modulate the function of B-cells and other T-cells through the secretion of 
cytokines. Further, the CD4+ cells can be divided into two subgroups based on the 
cytokine profile and predominant function. Type 1 CD4+ cells help directly in the cell-
mediated immune response, producing interferon-gamma (IFN-γ), tumor necrosis factor 
alpha and beta (TNF-α, TNF-β) and IL-2 which are pro-inflammatory cytokines. The 
type 2 CD4+ cells secreted IL-4, IL-5, IL-6, and IL-10 and have an opposite effect to 
Th1. They participate in the immediately hypersensitivity reactions and are important in 
the B-cell antibody-mediated immunity10. The CD4+ T-cells recognize antigen presented 
in the MHC class II molecules, and the MHC class II molecules are found mainly on 
APCs.  
The CD8+ T-cells or cytotoxic T-cells recognize antigen presented on the class I MHC 
molecules expressed at all cells. They act as killer’s, and kill “infected host cells”, which 
express the antigen-peptide in the MHC class I molecule on the cell surface. 
 
4.2.2 The adaptive immune system 
The adaptive immune system is specific and has “memory”. The memory is expressed as 
a rapid and strong secondary response to an antigen that earlier has given a primary 
immune response. In the primary immune response memory cells have developed from 
the clonally expanded B- or T-cells. The memory cells are long lived and they are in 
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continuously recirculation in the blood waiting for new attacks from earlier detected 
antigens.  
 
A complete activation of the T-cell requires two signals of which the first is antigen-
specific and delivered through the TCR. This first signal is required for the naïve T-cells 
to proliferate and differentiate, and is the interaction between the TCR on the T-cell and 
the antigen-peptide-MHC-complex on the APC (Figure 2). 
TCRMHCHC
APC
T-cell
 
 
Figure 2: The primary interaction between the MHC molecule on the antigen 
presenting cell (APC) and the T-cell receptor (TCR) on the T-cell. The antigen is 
coloured black on the figure.  
The second or costimulatory signal (Figure3) is not antigen-specific and is transmitted 
through interaction between other surface molecules on the T-cell and the APC. This 
signal is essential for the functional response in the T-cells, and is transduced through 
interaction between the cluster of differentiation 28 (CD28) molecules or cytotoxic T 
lymphocyte antigen 4 (CTLA4) molecules on the T-cell with B7 molecules on the APC. 
CD28- and CTLA4 molecules bind the same ligand (B7-1 and B7-2 molecules) on the 
APC, but the CTLA4 molecule has 50-100-fold higher binding activity than the CD28 
molecule. The CD28 molecule is expressed by naïve or immature T-cells and also this 
signal is essential for the initiation and progression of a T-cell response. Interaction 
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between the CTLA4- and the B7-molecule results in down-regulation of the ongoing 
immune response. Both the CTLA4 molecule and the inducible co-stimulatory (ICOS) 
molecule are expressed on activated- and memory T-cells only. ICOS is also important 
for the T-cell activation and proliferation. It is shown that without ICOS the immune 
response becomes deficient12. Most importantly, ICOS up-regulate the production of 
interleukin-4 (IL-4), resulting in immunoglobulin-isotype class switching and formation 
of the germinal centre 13,14. 
CTLA4
CD28
B7
B7h ICOS
TCRMHCHC
APC
T-cell
 
Figure 3: Both the first and second signal between the antigen presenting 
cell (APC) and the T-cell. The antigen is coloured black and the co-receptors 
are named in the figure. 
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4.2.3 The immune response in MS 
 
Figure 4: The complex immune response across the blood brain barrier (BBB) of a 
Multiple Sclerosis (MS) patient. From Sospedra et al, 2004 
 
The immune response in MS is complicated and not fully understood (see Figure 4). The 
immunological response in CNS is probably characterized by rupture of the blood brain 
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barrier (BBB) and mononuclear cell infiltration, resulting in destruction of myelin, death 
of oligodendrocytes and loss of axons. The lesions may occur anywhere in the CNS and 
vary in size. Most evidence support an autoimmune pathogenesis where lymphocytes, 
both CD4+ and CD8+ have a fundamental role. Peripherally activated autoreactive CD4+ 
lymphocytes cross the BBB and initiate chronic inflammatory response in the CNS, as 
documented in the experimental autoimmune encephalomyelitis (EAE), an animal model 
of MS15. These cells are probably also important players in the long-term evolution of the 
disease. Damage of the CNS is, however, most likely mediated by other components of 
the immune system, such as antibodies, complement, CD8+ T cells, and factors produced 
by innate immune cells. Several mechanisms in MS are still unclear, for example 
including what guides autoreactive CD4+ T cells to the CNS. However, antigen 
presentation is a critical requirement for the initiation and perpetuation of inflammatory 
responses within the CNS16. The traditional APCs are not present in the CNS, but MHC 
class II and costimulatory molecules as B7-1 and B7-2, are upregulated on microglia’s 
and macrophages in the setting of local inflammation. These can effectively present 
antigens17. 
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4.3  Genetic aspects of MS 
4.3.1 Genetic epidemiology of MS 
About 15-20 % of the MS patients have one or more affected relatives. Family 
aggregation is often evaluated by studying the relatives of the affected patient and 
establishing whether they are at higher risk of getting MS than the normal population. 
Studies have shown that first, second, and third degree relatives of people with MS have 
a higher risk of developing MS than the general population18. But this risk does not 
differentiate between shared environment and genetic background. Monozygotic twins 
(MZ) are by birth genetically identical, and by comparing the concordance rates between 
MZ and dizygotic twins (DZ) the estimation of the role of genetic factors involved in the 
disease has been done. Figure 5 show the different recurrence risk for a sibling to a MS 
patient. The risk for getting MS is highest for a monozygotic twin, approximately 25%19-
21 22,23 or children of parents who both have MS, approximately 30 % . These studies 
indicate that genes contribute to MS in addition to environmental factors. 
 
Figure 5: The recurrence risk for getting Multiple Sclerosis (MS) for a sibling to a MS 
patient. From Dyment et al, 2004 
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4.3.1 Strategies for genetic studies  
Natural sequence variations in the genome can be used as genetic markers. The two main 
markers used for genetic analysis are microsatellite or variant number of tandem repeats 
(VNTR) polymorphisms and single nucleotide polymorphism (SNP). Polymorphisms 
are variations in the genome sequence. A locus is polymorphic if there exists two or more 
normal alleles, with the rarest allele exceeding a frequency of 1 %. Alleles with 
frequency below 1% are called mutations.  
Microsatellites are short, tandemly repeated DNA sequences (Figure 6). The short repeat 
unit can be di-, tri-, - tetranucleotides or more, but the dinucleotide repeat is the most 
frequent seen in the genome. The microsatellites are widely spread in the genome and are 
also highly polymorphic. The mutation rate can be up to 10-3 per site per generation 
compared to an average of 10-8 for SNPs. 
GAGAGAGAGAGA                                                  6 repeats
GAGAGAGAGAGAGAGAGAGA                           10 repeats
GAGAGA                                                            3 repeats  
 
Figure 6: Three DNA segments showing different length of dinucleotide 
repeats (VNTR).  
 
SNPs are single base pair (bp) variations between normal individuals (Figure 7). The 
effect of a SNP depends on it’s location in the genome, e.g. in the coding region or non-
coding region, whether the mutation leads to different incorporated amino acid in the 
protein synthesis or stop in the protein synthesis. Normally the SNPs are a part of the 
human variation, but they can also be disease causing. 
A/G
 
Figure 7: A single nucleotide polymorphism (SNP) is a point mutation in the DNA 
sequence. 
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Genetic analysis is commonly divided into “Linkage analysis” and “Association 
me have 
 
 be 
on 
type is 
 
e 
sed 
association study. A classical family tree consist of at least three generations, but more 
analysis”. Linkage is a term used to describe that two loci on the same chromoso
a tendency to be inherited together more often than by chance alone. Linkage analysis 
can be used in families to identify genes associated with a specific phenotype. In complex 
diseases non-parametric sib pair methods referred as allele-sharing-test are used. Due to 
recombination during the meiosis, most genes are in linkage equilibrium, which means 
that they are transmitted to the offspring independently of each other. Alleles at loci that
are in linkage disequilibrium (LD) will be transmitted together to the offspring more 
often than expected from their respective allele frequencies. Alleles in LD tend then to
inherited as so-called haplotype. The recombination rates and the LD throughout the 
genome will vary, but the LD is always stronger when the loci are close to each other 
the chromosome. Regions with high LD are often named conservative regions.  
Figure 8 below show the difference between a genotype and a haplotype. A geno
the alleles specific for a locus, whereas a haplotype is alleles at different loci that are 
inherited together on the same DNA strand. 
 
Association studies test whether a particular allele occurs at higher frequency among 
Genotype: 
Haplotype:
A-A
A-G
G-G
A/G
Figure 8: The difference between a genotype and a haplotype.
affected than unaffected individuals. Case-controls studies are the most common study
design in the association studies. In a specific locus the case-controls studies compare th
allele frequencies of a set of unrelated affected individuals (the cases) to a set of 
unrelated unaffected controls (the controls). Another study design is the family-ba
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often used for complex disease research is the “TRIO-families”, which consist of the 
affected persons and theirs parents. The advantage with TRIO based association studies 
are that the ethnically control material is well matched, since the parent’s non-transmitted 
alleles are used as controls. 
Genetic studies can also be performed as genome-wide screens or candidate gene studies. 
The genome wide screens have mainly been performed using linkage analysis, and have 
 to 
been successfully applied in many monogenetic studies. In studies of the complex traits, 
as MS, the screens have been more disappointing, and the linkage approach has been 
complemented with genome wide screens using association analysis. Candidate gene 
studies investigate genes that are selected based on their potential biological relevance
a disease.  
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4.3.2 Genetic studies in MS 
Both candidate gene studies and genome-wide screens have been used to detect genes 
involved in developing MS. Strongest association and linkage is found to the HLA gene 
region, but several other genes have shown positive findings in many studies, among 
these are the T-cell-receptor , SH2D2A and CTLA4 genes, and regions at chromosome 5 
and chromosome 17. 
 
HLA gene region 
The human leukocyte antigen (HLA) gene region was the first described gene region, that 
showed an association with MS and other autoimmune diseases. The HLA region 
involves 3600k bp on the short arm of chromosome 6 (6 p21-22), a highly polymorphic 
region, which consists of several genes, divided into classes; HLA class I genes (A, B and 
C loci), HLA class II genes (DR, DQ and DP loci) and HLA class III genes ( for example 
TNF) (Figure 9) 
DP  DQ DR   TNF      B C   A      F                       HFE
class II       class III         classical class I extended class I
centromeric telomeric  
 
Figure 9: Chromosome 6 and the genes at 6p21-22 in the human leukocyte antigen 
(HLA) gene region. 
The first genetic association with MS was reported in 1972 for HLA class I antigens A3 
and B724,25. Some years later association with MS to HLA class II was shown. The 
strongest and most consistent association is found with the extended haplotype HLA 
DRB1*1501, DQA1*0102, DQB1*0602 (DR1501 or DR2) haplotype26. This haplotype is 
especially frequent in Northern Europe. In a Norwegian material of 243 MS patients and 
296 randomly colleted Norwegian controls, the frequency for the HLA DRB1*1501, 
DQA1*0102, DQB1*0602 haplotype was found to be 36.2% among MS patients and 
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2716.5% among the controls . Similar frequencies are also found in British and Swedish 
studies26,28. The HLA-DR2 haplotype was more frequent among female patients, and was 
negatively correlated with age at time of diagnosis regardless of sex both in an English, 
Swedish and Norwegian study1,28,29. 
Several non-northern European populations have different DRB1 associations with MS. 
Both MS in Sardinia, Canary Islands and Turkey have in additional to the HLA DRB1 15 
haplotype an association with the DR4 allele (DRB1*0405)30-32.  
It has also been reported that genes located in the HLA complex outside the class II 
region are associated with MS. Among Swedish patients, the HLA-A*0301 allele was 
found to increase the risk of MS independently of the HLA-DR2 haplotype, whereas the 
HLA-A*0201 allele was found to decrease the risk of MS33. Similar results were recently 
replicated in a Norwegian study, where we found an independent additional effect to 
genetic susceptibility of HLA class I in MS. The study found a higher “genotypic relative 
risk” in individuals carrying both HLA DR2 and HLA A3 (HLA-A*0301), compared to 
those who carry only HLA DR2 or only HLA A327. 
 
Genome-wide Screens for Linkage in MS 
The first three genome-wide screens for linkage studies preformed in MS were published 
in 199634-36. None of these screens could define new susceptibility loci, but there were 
more regions with suggestive and potential linkage, than expected by chance alone. Since 
these first publications, several genome-wide screens have been performed in other 
populations, including the Nordic countries37,38. However, few screens have overlapping 
results. In 2004 a large meta-analysis with 719 families from the Europe, USA and 
Canada was preformed. This screen reveled for the first time significant linkage in the 
HLA region in MS due to improved power caused by including a high number of families 
39. 
 
GAMES (Genetic Analysis of Multiple sclerosis in EuropeanS) was a big European 
collaboration project performing a genome-wide screen for LD in MS. By using a 
collaborative network, large datasets of cases and controls were collected. The individual 
DNA samples were pooled together and around 6000 microsatellite markers were typed 
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40for these pools of DNA. Follow-up studies of the GAMES screens are in progress . 
 
Other candidate gene regions in MS  
A long list of candidate genes has been studied in MS. Among the most interesting genes 
is the CTLA4 gene, which is the main focus at this present work (see next paragraph).  
In addition, the SH2 domain protein 2A gene (SH2D2A), located in the chromosome 
1q21 region, has been an interesting candidate gene to study (see related paper41,42). 
This gene encodes the T cell specific adaptor protein (TSAd), which was first described 
to be expressed in activated human T-cells43. It has been implicated in modulation of 
proximal signaling events, as well as in transcriptional regulation in human T-cells. A 
variant number of tandem repeats (VNTR) polymorphism was found in the gene’s 
promoter region. Recent studies indicate that homozygosity for short (ie GA(13) and 
GA(16)) alleles for this polymorphism, is associated with development of MS41. This 
finding is replicated in other autoimmune diseases such as juvenile rheumatoid arthritis 
(JRA)42. Thus, these studies support the notion that the short alleles of the SH2D2A 
promoter polymorphism may contribute to the genetic susceptibility in autoimmune 
diseases.  
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4.3.3 The CD28/CTLA4/ICOS gene region  
Chromosome 2q33 encodes a set of genes, which are essential for several functions in the 
T-cell. Among these are the CTLA4 gene, the CD28 gene and the ICOS gene (Figure 10).  
CD28 ICOSCTLA4
kb0 100 200 300
 
Figure 10: Chromosome 2 and the genes at 2q33. From centromeric the cluster of 
differentiation 28 (CD28) gene, the cytotoxic T lymphocyte antigen 4 (CTLA4) and most 
telomeric the inducible co-stimulatory (ICOS) gene. 
  
These three molecules are all located on the T-cell surface showed in Figure 11. These 
. 
 finally 
genes have been of interest since they all play an important role in the immune response
The hypothesis is that mutations or polymorphims in these genes resulting in a 
dysfunction in the molecules can implicate and disrupt the immune response and
contribute to an autoimmune disease. 
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Figure 11: The different cell surface molecules on the antigen presenting cell (APC) 
and the T-cell. The antigen is coloured grey and the co-receptors are all named in the 
figure. 
  
Especially, the CTLA4 gene has been shown to be linked to and associated with several 
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Recently, a new candidate gene polymorphism in the CTLA4 region was reported to 
 
 
as 
autoimmune diseases44. In a Norwegian material an association with the CTLA4+49 
polymorphism in MS was reported in 1999. A series of genetic analyses of the CTLA
gene and other closely located genes have thereafter been reported in MS (for overview
see Teutsch et al45), but diverse findings have been reported. An increase in disability has
been found to be associated with the CTLA4 +49 AA genotype46, as well as association 
of the G allele with a PP-MS disease course47. Other studies have not shown associations
neither with age at onset, disease course nor severity48,49. 
influence gene splicing and thereby the relative abundance of soluble CTLA450. A 
decrease in soluble CTLA4 protein will result in incomplete down-regulating of the
immune response, a mechanism that may be involved in development of autoimmune
disease. Association was shown for a haplotype including the CT60 single nucleotide 
polymorphism (SNP) (located 0.2 kb 3’ of the CTLA4 transcript), in Graves’ disease, 
autoimmune hypothyroidism and type 1 diabetes50. Association with this gene region h
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also been found in celiac disease51 and Addison’s disease52. Few studies have shown an 
association with autoimmune diseases to the CD28 and ICOS genes in spite of the 
important functions of these genes. 
On this background, this work has focused on a candidate gene association study in the 
CD28/CTLA4/ICOS gene region in MS. 
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5 AIMS OF THE STUDY 
The overall aim of this study has been to investigate genetic factors contributing to 
disease susceptibility to MS.  
 
The specific aims of this work have been to: 
1) Reevaluate the previous association found in the CTLA4 region with MS in a new 
material. The investigated region has been expanded and additional markers have 
been used to find out if the previously association is primary or secondary to a 
nearby region. 
2) Analyze distribution of alleles in different clinical and genetic subgroups of MS. 
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6 METHODOLOGICAL CONSIDERATIONS 
6.1 The patients and controls 
Most of the MS patients included in this study are collected in Oslo or its suburban areas. 
The majority of these patients were recruited through their contacts with Department of 
Neurology, Ullevål University Hospital. A few were recruited through MS Societies and 
other neurological departments serving the suburban Oslo areas. An additional population 
of MS patients was recruited from the Department of Neurology, Haukeland University 
Hospital in Bergen. All patients included in this study have been diagnosed in 
neurological departments, and all fulfilled the Poser criteria for MS6.  
All control samples were randomly collected among healthy blood donors recruited 
through the Norwegian Bone Marrow Registry. The study was approved by the Regional 
Medical Research Ethics Committee. 
 
6.2 Genotyping 
6.2.1 The PCR method 
The first publication of the polymerase chain reaction (PCR) technique was released in 
198553. The technique amplifies a specific DNA segment, and the method is sensitive 
enough to detect as little as one DNA molecule in almost any type of sample, as blood-, 
hair root- and sputum/mucous membrane samples. 
Selective amplification requires information about the DNA sequences flanking the target 
DNA. This information can be found in genetic databases or detected through sequencing 
the region. Based on this information, two oligonucleotides or primers are designed. The 
primers are complementary to short sequences outside the 3’endes on the DNA strands. 
PCR is a chain reaction where the synthesized DNA strands act as template for further 
DNA synthesis. A PCR-cycle consists of at least three steps, and the steps are 
temperature- and time specific. The first step is the denaturation of the double stranded 
DNA, the second step is the annealing of the primers. The third step is the DNA synthesis 
using a heat-stable DNA polymerase (Taq Polymerase). 
The number of cycles are usually between 25 and 30, resulting in a specific DNA 
segment in at least 10^5 copies. The specific DNA segment can be visualized as a distinct 
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band of a specific size on a gel electrophoresis. 
 
6.2.2 The PCRs in this study 
The primers were either obtained through the Genome Database (http://ww.gdb.org) or 
established in previous projects. The CT60 (rs3087243) and CT61 (rs11571319) SNPs 
were genotyped as one haplotype by amplifying a polymerase chain reaction (PCR) 
product including both SNPs, which was separated by 18 base pairs (forward primer 
5’TATCCATCCTCTTTCCTTTTGA, reverse primer 
5’AAATCAATTGGCATGCTGTTTAAC). 
The microsatellite markers were amplified separately by PCR in a reaction volume of 
10 µl containing low salt buffer, 8 nmol dNTP, 1.6 pmol of each primer, 0.16 U Taq 
Polymerase and 40 ng DNA or in a reaction volume of 8 µl containing 1xMastermix 
(http://www.ahdiagnostics.com), 2.2 pmol of each primer and 40 ng of DNA.  
The SNP markers were amplified in a 20 µl reaction volume using MgCl2-free PCR 
buffer, 50 nmol MgCl2, 8 nmol dNTP, 4 pmol of each primer, 0.8 U Taq Polymerase and 
20ng of DNA.  
Thermal cycling conditions were: 95°C 20 seconds, 56-60°C 30 seconds (depending on 
the annealing temperature), 72°C 60 seconds, 35 cycles ran on a Peltier Thermal Cycler 
(MJR Research, Watertown, MA). 
 
6.2.3 Genotyping by use of PCR restriction length polymorphism 
method 
Restriction enzymes are enzymes able to cut DNA into fragments. A given enzyme 
recognizes a specific sequence of 4-8 nucleotides, and this is called the restriction site. 
The PCR-restriction length polymorphism (PCR-RFLP) method is based on a difference 
in one nucleotide among individuals, and is therefore a method for detecting SNPs. The 
PCR product has the SNP inside the fragment and the SNP is also located in a restriction 
site for a given restriction enzyme. Depending on the nucleotide in the SNP position the 
used restriction enzyme will or will not recognize the site and either cut or not cut the 
DNA segment. There are three possible genotypes for each individual sample; 
homozygote for wild or mutant nucleotide in the SNP, or heterozygote (see Figure 12).  
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Figure 12: There are three possible genotypes at a polymorphic locus. 
The DNA fragment from the individual samples will be visualized as distinct bands on a 
gel electrophoresis. With standard bands in the same run, the genotype for each 
individual sample can be determined. 
 
6.2.4 Genotyping by use of TaqMan® technology 
TaqMan® Technology integrates a PCR-based assay with laser scanning technology to 
excite fluorescent dyes present in the specially designed TaqMan® probes. The ABI 
PRISM® 7000 Sequence Detection System (Applied Biosystems, Foster city, California, 
USA) can be used for assays such as allelic discrimination (SNP detection). In our study 
we used a 384-well assay. Data were collected and analyzed with software from Applied 
Biosystems, TaqMan® program SDS2.1. Negative controls and controls with known 
genotype for the marker (homozygote or heterozygote) were run in every PCR subset. 
 
6.2.5 Genotyping by use of DNA sequencer 
The PCR products can be amplified using primers labeled with different fluorochromes. 
The length of the PCR product can be detected when these PCR products are separated in 
a DNA sequencer together with an internal size standard. In our study the microsatellite 
alleles were identified according to length by analyzing the PCR products on an ABI 
Prism® XL 337 sequencer (Applied Biosystems, Foster city, California, USA). Data 
were collected and analyzed with the Gene Scan® 2.1 and the Genotyper® 2.0 programs. 
Controls with known length were included in each run, and blank control samples were 
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run in every PCR subset.  
 
6.2.6 Genotyping by use of melting gel electrophoresis 
The melting gel electrophoresis theory is based on the observation that double-stranded 
DNA fragments melt to single-stranded DNA when exposed to denaturants such as urea, 
formamide and/or temperature. The double-stranded DNA fragments have different 
melting properties depending on the nucleotide sequence and length of the fragments. 
When exposed to denaturants the PCR amplified fragments with only minor difference 
like a point mutation, can be detected based on their differential melting point and 
migration in a polymer-filled capillary. Fischer SG et al54 have described the 
methodology in more details. 
Denaturant capillary electrophoresis (DCE) is based on the melting gel theory55-57, and is 
a method for genotyping of SNPs. By comparing the peak pattern with a heterozygous 
standard run simultaneously with a different florochrome, the individual samples could 
be genotyped. The SNPs CTLA4+49, CT60 and CT61 were genotyped using DCE. 
 
The SNP typing was performed on a standard multicapillary DNA sequencing instrument 
MegaBASE™ 1000 DNA Analysis System (Amersham Pharmacia Biotech, Oslo, 
Norway). The CTLA4 +49 SNP was separated by a gradient of 58-54°C cycled 20 times, 
followed by constant temperature at 50°C. The CT60 and CT61 alleles (i.e. the 
combination of the CT60 and CT61 microhaplotypes) were separated by cycling the 
temperature between 50-47°C 40 times, followed by lowering the temperature to 45°C 
until the end of the run. The peak patterns were then analyzed and compared with a 
heterozygous standard by a Genotype program named “View and Edit” from 
MegaBASE™ software. 
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6.3 Statistical considerations 
In our study the case and control materials were compared by the Chi square test using 
the Public Domain Software for Epidemiology and Disease Surveillance EPI Info 
Version 5.01b (Center of Disease Control, Epidemiology Program Office, Atlanta, GA, 
USA). Global chi square values and global p-values were calculated for each marker, 
after having grouped alleles with frequencies below 0.05 in cases and controls into one 
group. Since none of the global p-values reached statistical significance at the level of 
0.05, only uncorrected p-values are given. The haplotype frequencies were estimated by 
the expectation-maximization (EM) algorithm using the COCAPHASE program 
available through the Genetic Linkage User Environment (GLUE) application at Human 
Genome Mapping Project Resource center (HGMP-RC) (www.hgmp.mrc.ac.uk). Hardy-
Weinberg equilibrium was calculated manually or using Arlequin software 
(http://anthro.unige.ch/arlequin). Clinical correlations and logistic regression analysis was 
performed using NCSS 2004 (Number Cruncher Statistical Systems; www.ncss.com). 
 
 33
7 SUMMARY OF RESULTS 
 
We have investigated in this study a 262 kb region of chromosome 2q33, covering the 
CD28, ICOS and CTLA4 genes, in a clinically well characterized Norwegian MS cohort. 
Six microsatellites; CD28-A, CD28-B, SARA-43, SARA-1, SARA-31 and SARA-47 and 
three SNPs; CTLA4+49, CT60 and CT61 were genotyped (Figure 13).  
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Figure 13: Genes and markers at chromosome 2q33 investigated in this study.  
 
All result tables are placed at the end of this chapter. 
 
DCE methodology was selected for the SNP genotyping 
When starting up the present study, we experienced some technical difficulties using the 
PCR-RFLP methodology that was applied in our previous study58. In that study the 
amplified product was determined by sequential digestion with the restriction enzymes 
TseI and MseI. We performed an explorative comparison between the different SNP 
genotyping methods; PCR-RFLP-, TaqMan®- and denaturant capillary electrophoresis 
(DCE)-analysis. 
 
Genotyping of the CTLA4+49 marker in 189 controls showed different results (Table 3) 
in 25 samples when comparing PCR-RFLP data with TaqMan® data, and in 24 samples 
when comparing PCR-RFLP data and DCE data (typing error 13 %). When comparing 
TaqMan® and the DCE data, two samples were genotyped with different result (typing 
error 1 %).  
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 Table 4 shows the comparison between the different methods when analyzing the specific 
genotypes. In the RFLP-PCR method the GG-genotype was more often found, than using 
other methods as TaqMan® and DCE. Based on these results, the DCE method was 
selected for further SNP typing, and only the DCE data are included in the analyses 
presented in this study. 
 
No associations were found to markers in the CD28/CTLA4/ICOS gene 
region 
Genotyping of the nine markers in the CD28/CTLA4/ICOS gene region (CD28-A, CD28-
B, SARA-43, CTLA4+49, CT60, CT61, SARA-1, SARA-31 and SARA-47) in the first 
material of MS patients (n=302) and controls (n=282), showed no significant differences 
in the global analysis of allele frequencies (Table 5). 
 
Since the CTLA4 gene previously has been reported to be associated with MS in some 
studies, a second material of Norwegian MS cases (n=273) and controls (n=269) was 
genotyped for the CTLA4, CT60 and CT61 SNPs. No significant deviations in allele 
frequencies or genotype frequencies were found in this second material (Table 6). The 
association was neither not found in the total material of 575 MS cases and 551 controls 
(Table 6). 
 
CTLA4+49, CT60, CT61 haplotype frequencies in the MS cases and controls were also 
compared without showing significant associations (Table 7). 
 
No associations were found after stratification of the material 
Stratifying the part of the material that previously has been typed for the HLA-DR1502, 
DQ0602 haplotype (n= 274 MS cases and n=300 controls), did not reveal additional 
information (data not shown).  
 
Furthermore, the frequencies of genotypes and haplotypes for markers in the CTLA4 
region showed no correlations neither to sex (n= 485), disease course (n= 453), nor 
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presence or absence of familial cases of MS (n= 448) (Table 8).There were no 
associations to age at onset (data not shown). Logistic regression analysis including these 
clinical variables and genotyping data did not reveal additional information. 
 
Power and Hardy-Weinberg calculations 
All SNP markers in the control material were found to be in Hardy Weinberg equilibrium 
(data not shown). Power calculations for the six microsatellites were done, showing that 
this study could not show an OR below 1.5. 
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Result tables in this study: 
PCR-RFLP TaqMan® DCE
Genotype
AA 0.32 0.33 0.33
AG 0.46 0.49 0.49
GG 0.22 0.18 0.18
Allele
A 0.55 0.57 0.57
G 0.45 0.43 0.43
 
Table 3: Genotype and allele frequencies of the CTLA4+49 polymorphism in 189 
randomly collected Norwegian healthy controls achieved by different methods. 
 
PCR-RFLP to TaqMan® PCR-PFLP to DCE TaqMan® to DCE
Differents
GG > GA 16 16 1
GA > GG 8 7 1
GA > AA 1 1
25 24 2
Typing error
freqency 0.13 0.13 0.01
 
Table 4: Comparing genotyping errors using different methods. 
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A lle le M S C o n tro l a  x 2 g lo b a l 
b  p  g lo b a l n c
c C D 2 8 -A 2 n = 5 9 4 2 n = 5 6 4 4 .3 0 0 .2 5
2 3 1 0 .0 6 0 .0 3
2 3 5 0 .8 1 0 .8 5
2 3 7 0 .0 7 0 .0 5
o th e r 0 .0 7 0 .0 7
c C D 2 8 -B 2 n = 5 9 0 2 n = 5 6 0 5 .5 7 0 .2 3
1 9 8 0 .3 3 0 .3 9
2 0 0 0 .1 8 0 .1 8
2 0 2 0 .1 2 0 .1 9
2 0 4 0 .3 5 0 .3 9
o th e r 0 .0 1 0 .0 1
c S A R A -4 3 2 n = 5 9 2 2 n = 4 9 8 1 0 .2 4 0 .0 7
2 1 8 0 .1 4 0 .1 1
2 2 0 0 .0 9 0 .0 6
2 2 2 0 .4 9 0 .5 5
2 2 4 0 .0 7 0 .0 8
2 2 6 0 .1 6 0 .1 3
o th e r 0 .0 5 0 .0 6
d C T L A 4  + 4 9  n = 2 4 0 n = 2 4 1 0 .7 1 0 .4 0
A 0 .5 5 0 .5 9
G 0 .4 5 0 .4 1
d C T 6 0  n = 2 6 1  n = 2 6 7 0 .5 4 0 .4 6
A 0 .4 0 0 .4 3
G 0 .6 0 0 .5 7
d C T 6 1  n = 2 6 1  n = 2 6 7 0 .3 5 0 .5 6
A 0 .1 5 0 .1 7
G 0 .8 5 0 .8 3
c S A R A -1 2 n = 5 9 4 2 n = 4 9 8 3 .2 7 0 .3 5
2 6 0 0 .0 5 0 .0 6
2 6 4 0 .2 9 0 .3 3
2 6 8 0 .2 8 0 .2 7
2 7 2 0 .3 6 0 .3 2
o th e r 0 .0 2 0 .0 2
c S A R A -3 1 2 n = 6 0 2 2 n = 4 9 8 1 .6 9 0 .4 3
2 1 1 0 .5 0 0 .5 1
2 1 7 0 .4 9 0 .4 9
o th e r 0 .0 0 0 .0 0
c S A R A -4 7 2 n = 6 0 4 2 n = 4 9 8 2 .8 6 0 .4 1
1 4 9 0 .3 7 0 .3 3
1 5 1 0 .3 4 0 .3 4
1 5 3 0 .2 4 0 .2 7
o th e r 0 .0 5 0 .0 6
 
Table 5: Allele frequencies for analyzed chromosome 2q33 markers in the first 
Norwegian MS patients and controls material. 
a х2global = global chi square value, not corrected for number of comparisons 
b p global nc = global p-value, not corrected for number of comparisons 
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 Genotype a MS I b MS II a Control I b Control II MStotal Controltotal c x2global total 
d p global nc total
CTLA4 +49  n=240 n= 273 n=241 n=268 n=513 n=509 0.37 0.83
AA 0.29 0.34 0.35 0.32 0.32 0.33
AG 0.52 0.47 0.49 0.49 0.49 0.49
GG 0.19 0.19 0.16 0.19 0.19 0.18
CT60  n=261  n=217  n=267  n=269 n=478 n=536 0.59 0.75
AA 0.17 0.18 0.18 0.15 0.18 0.17
AG 0.45 0.49 0.49 0.50 0.47 0.49
GG 0.38 0.33 0.33 0.35 0.35 0.34
CT61  n=261  n=217  n=267  n=269 n=478 n=536 0.48 0.48
AA 0.02 0.02 0.04 0.01 0.02 0.03
AG 0.27 0.26 0.25 0.29 0.27 0.27
GG 0.71 0.72 0.71 0.70 0.71 0.70
Allel a MS I b MS II a Control I b Control II MStotal Controltotal c x2global total 
d p global nc total
CTLA4 +49  n=240 n= 273 n=241 n=268 2n=1026 2n=1018 0.37 0.54
A 0.55 0.58 0.59 0.57 0.57 0.58
G 0.45 0.42 0.41 0.43 0.43 0.42
CT60  n=261  n=217  n=267  n=269 2n=956 2n=1072 0.01 0.91
A 0.40 0.43 0.43 0.40 0.41 0.41
G 0.60 0.57 0.57 0.60 0.59 0.59
CT61  n=261  n=217  n=267  n=269 2n=956 2n=1072 0.51 0.48
A 0.15 0.15 0.17 0.16 0.15 0.16
G 0.85 0.85 0.83 0.84 0.85 0.84
 
 
Table 6: CTLA4 +49, CT60 and CT61 allele and genotype frequencies in the different 
sets of Norwegian MS patients and controls. 
a the first material of Norwegian multiple sclerosis (MS) cases and randomly 
collected healthy controls 
b the second material of Norwegian MS cases and controls 
c x2global all = global chi square value for the total material 
d  p global nc all  = global p-value for the total material, not corrected for number of 
comparisons 
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 Haplotype a MS a Control b x2global
c p global nc
2n=878 2n=974
A, A, G 0.40 0.40 0.04 0.85
A, G, A 0.14 0.16 0.51 0.47
G, G, G 0.44 0.42 0.38 0.54
other 0.02 0,02
 
 
Table 7: CTLA4+49, CT60, CT61 haplotype frequencies in Norwegian MS patients 
and controls. 
a total population of multiple sclerosis (MS) patients and controls 
b х2global = global chi square value 
c p global nc = global p-value, not corrected for number of comparisons 
 
 40
female male a RRMS b PPMS no yes
Genotype
CTLA4+49 n=334 n=151 n=372 n=81 n=373 n=75
AA 0.32 0.30 0.34 0.25 0.32 0.28
AG 0.50 0.50 0.48 0.50 0.49 0.49
GG 0.18 0.20 0.18 0.25 0.19 0.23
CT60 n=326 n=145 n=363 n=82 n=360 n=77
AA 0.18 0.15 0.19 0.15 0.18 0.18
AG 0.46 0.46 0.47 0.41 0.40 0.47
GG 0.34 0.39 0.34 0.44 0.42 0.35
CT61 n=326 n=145 n=363 n=82 n=360 n=77
AA 0.01 0.03 0.01 0.03 0.00 0.02
AG 0.26 0.27 0.28 0.21 0.25 0.27
GG 0.73 0.70 0.71 0.76 0.75 0.71
Allele
CTLA4+49 2n=666 2n=302 2n=742 2n=162 2n=744 2n=150
A 0.57 0.55 0.58 0.50 0.53 0.57
G 0.43 0.45 0.42 0.50 0.47 0.43
CT60 2n=652 2n=290 2n=726 2n=164 2n=720 2n=154
A 0.42 0.38 0.43 0.35 0.38 0.41
G 0.58 0.62 0.57 0.65 0.62 0.59
CT61 2n=652 2n=290 2n=726 2n=164 2n=720 2n=154
A 0.14 0.16 0.15 0.14 0.12 0.15
G 0.86 0.84 0.85 0.86 0.88 0.85
Sex Disease course Familial cases of MS
 
Table 8: Allele and genotype frequencies in clinical subgroups according to 
disease course and demographic variables in Norwegian MS patients. 
a RRMS = relapsing remitting disease course 
b PPMS = primary progressive disease course 
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8 GENERAL DISCUSSION 
 
Chromosome region 2q33 encodes several regulators of the immune system, among these 
the CTLA4, CD28 and ICOS molecules. Involvement of these genes in MS is not yet 
clear. We investigated six microsatellites and three SNPs in a relatively large and 
clinically well characterised Norwegian MS cohort. No associations were observed for 
any of the markers analysed in 575 MS patients and 551 controls. Associations were 
neither found when stratifying the material for the HLA-DR1501 haplotype, sex, age at 
onset, disease course nor familial aggregation. In conclusion, this study could not confirm 
association with the CD28/CTLA4/ICOS gene region. 
 
When investigating candidate genes and genetic markers, the initial positive report of an 
association, is often followed by subsequent negative findings. A recent review reported 
that up to 95% of initial claims of association cannot be replicated59. The authors 
suggested that the most important factors behind the inability to replicate previous 
positive association were “publication bias, failure to attribute results to chance and 
inadequate samples sizes”. Several of these factors may have contributed to the fact that 
this study can not confirm previously positive findings. 
 
Our methological evaluation identified a divergent result between the PCR-RFLP method 
and the two other methods (DCE and the TaqMan®) (Table 3 and 4). These analyses 
showed that both the DCE and the TaqMan® methods were superior to the RFLP method 
for accurate genotyping of the selected SNPs. Incorrect genotype frequencies might 
therefore have appeared in both our own and other’s previous studies reporting RFLP 
based CTLA4+49 analyses. Methodical evaluations are seldom reported, but are 
obviously of great value to a genetic study.  
 
All available MS patients and controls were genotyped for the CTLA4, CT60 and CT61 
SNPs by using the DCE methodology in the present study. DCE was selected before 
TaqMan® genotyping due to our previous experience with this methodology showing 
that DCE is a reliable and low cost tool for high-throughput SNP analysis. The previously 
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obtained RFLP data were only included in methodology studies. In order to present data 
that are consistently genotyped by use of the same methodology, only DCE SNP data are 
included in all statistical analyses. Since all the material of MS patients and controls 
SNPs now only is genotyped by using DCE technology, the frequency of genotyping 
inconsistencies should be low in both the first and second Norwegian MS cohorts 
presented in this study.  
 
Non-significant, but interesting differences in genotype frequencies between the two 
materials were still observed in this study (Table 6). Both materials are established by 
random selection among Norwegians, thus ethnical differences can not explain the 
differences between the two sets of Norwegian cases and controls. Even though it is very 
important to match the control group with the patient group, an undetected stratification 
may have appeared in the control material. Recently, an Icelandic study showed that the 
difference between “randomly collected controls” is more divergent than excepted60. To 
reduce this stratification risk one might rather analyze TRIOs (the patients and their 
parents) instead of case-controls materials. The parents can then be used as controls, and 
Mendelian consistency can be used as an internal check for genotype errors.  
 
It has been suggested that “inadequate samples sizes” is an important factor behind the 
inability to replicate previous positive associations59. The results obtained in published 
MS studies about the CTLA4 region, have been inconsistent45,61, probably partly due to 
small datasets. Usally below 300 cases and 300 controls or below 185 families have been 
included47-49,58,62-64. A recent meta-analysis of nine of the Caucasian datasets of MS 
patients typed for the CTLA4+49 polymorphism, did not reveal significant 
associations45.Table 9 shows this analysis where OR for all the studies together are close 
to one, showing that there is no significant association with MS in these CTLA4 studies. 
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Table 9: Meta-analysis of CTLA-4 exon 1 +49 G allele carrier frequency in nine 
comparable datasets of MS patients and controls (a) Data analyzed using a fixed 
effects model. (b) Data analyzed using a random effects model. From Teutsch et al, 2004 
 
The meta-analysis of seven of the same datasets comparing the CTLA4+49 
polymorphism in MS patients with different clinical courses did not show associations 
(not shown)45. The first Norwegian report58 was included in these meta-analyses. In line 
with this meta-analysis, the differences between cases and controls declined when we 
combined our data sets to a large MS case and control cohort. This observation 
emphasizes strongly the importance of including large materials in case-control analyses 
of candidate genes in a complex disease like MS.  
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Association with the CTLA4 gene region has been found in many autoimmune diseases, 
among these are Graves’ disease, autoimmune hypothyroidism, type 1 diabetes50, celiac 
disease51 and Addison’s disease52.These findings have been of importance for the 
postulation that the CTLA4 gene is important in developing autoimmune diseases. As 
previously mentioned, studies on gene splicing have found an influence between slicing 
forms and relative abundance of soluble CTLA450. A decrease in soluble CTLA4 protein 
resulted in incomplete down-regulating of the immune response, a mechanism that have 
been postulated to be involved in development of autoimmune diseases. However, it 
seems like MS is not associated with CTLA4, in contrast to some other autoimmune 
diseases. This could indicate that the pathogenesis of MS differ somehow from the 
pathogenesis of some other autoimmune diseases.
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9 FUTURE STUDIES 
 
The study of the CD28/CTLA4/ICOS gene region in MS presented here, adds to the 
findings in other recent publications that this genetic region dose not seem to make a 
major contribution to the genetic susceptibility in MS. Thus, our future studies will be 
focused on other candidate regions, as the HLA class I region at chromosome 6 and the 
SH2D2A gene at chromosome 1. Since studies in these genetic regions have already been 
performed (see paper 2 and 3) with interesting findings, further studies are ongoing. 
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